Pharmacokinetics and pharmacodynamics of glycopeptides;Pharmacocinétique et pharmacodynamie des glycopeptides

Antibiotiques

Volumn 5, Issue 2, 2003, Pages 89-98

  Jehl, Francois ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Glycopeptides; Pharmacodynamics; Teicoplanin; Vancomycin

Indexed keywords

POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL STRAIN; BONE TISSUE; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFORMATION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TOLERANCE; HEART; HUMAN; LUNG PARENCHYMA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATIENT COMPLIANCE; PREDICTION; REVIEW; TISSUE DISTRIBUTION;

EID: 0037959548     PISSN: 12945501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. CAMPOLI-RICHARD DM, BROGDEN RX, FAULDS D. Teicoplanin : a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1990 ; 40 : 449-86.
2. BROGDEN RX, PETERS DH. Teicoplanin : a reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drug 1994 ; 47 : 823-54.
3. SIDI V, ROILIDES E, BIBASHI E, et al. Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and Gram-positive bacteremia. J Chemother 2000 ; 12 : 326-31.
4. HARDING I, SORGEL F. Comparative pharmacokinetics of teicoplanin and vancomycin. J Chemother 2000 ; 12 : 15-20.
5. WOOD MJ. Comparative safety of teicoplanin and vancomycin. J Chemother 2000 ; 12 : 21-25.
6. LORTHOLARY O, TOD M, GASSELIN-DURAND B, et al. Stratégie d'utilisation des glycopeptides chez les adultes neutropéniques fébriles. Med Mal Infect 1997 ; 27 : 979-83.
7. WILSON APR. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 2000 ; 39 : 167-83.
8. ROWLAND M. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 1990 ; 18 : 184-209.
9. ASSANDRI A, BERNAREGGI A. Binding of teicoplanin to human serum albumin. Eur J Clin Pharmacol 1987 ; 33 : 191-5.
10. BERNAREGGI A, DANESE A, COMETTI A et al. Pharmacokinetics of individual components of teicoplanin in man. J Pharmacokinet Biopharm 1990 ; 18 : 525-43.
11. DELFAVERO A, PATOIA L, ROSINA et al. Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses. Antimicrob Agents Chemother 1991 ; 35 : 2551-7.
12. OUTMAN WR, NIGHTINGALE CH, SWENEY KR, et al. Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance dose. Antimicrob Agents Chemother 1990 ; 34 : 2114-7.
13. SMITHERS JA, KULMALA KH, THOMPSON GA, et al. Pharmacokinetics of teicoplanin upon multiple dose intravenous administration of 3, 12, and 30 milligrams per kilograms of body weight to healthy male volunteers. Antimicrob Agents Chemother 1992 ; 36 : 115-20.
14. THOMPSON GA, SMITHERS JA, KENNY MT, et al. Pharmacokinetics of teicoplanin upon multiple dose intravenous administration to normal healthy male volunteers. Biopharm Drug Disp 1992 ; 13 : 213-20.
15. DYKHUIZEN RS, HARVEY G, STEPHENSON N et al. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother 1995 ; 39 ; 1842-7.
16. PLEASANTS RA, MICHALETS EL, WILLIAMS DM, et al. Pharmacokinetics of vancomycin in adult cystic fibrosis patients. Antimicrob Agents Chemother 1996 ; 40 : 186-90.
17. HEALY DP, POLK RE, GARSON ML, et al. Comparision of steady-state pharmocokinetics of two dosages regimen of vancomycin in normal volunteers. Antimicrob Agents Chemother 1987 ; 31 : 393-7.
18. BLOUIN RA, BAUER LA, MILLER DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982 ; 21 : 575-80.
19. MATZKE GR, MCGORY RW, HALSTENSON CE, et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984 ; 25 : 433-7.
20. WYSOCKI M, DELATOUR F, FAURISSON F. et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections : prospective multicenter randomized study. Antimicrob Agents Chemother 2001 ; 45 : 2460-7.
21. POU L, ROSELL M, LOPEZ R, et al. Changes in vancomycin pharmacokinetics during treatment. Ther Drug Monitor 1996 ; 18 : 149-53.
22. YASUHARA M, IGA T, ZENDA H, et al. Population pharmacokinetics of vancomycin in japanese adult patients. Ther Drug Monitor 1998 ; 20 : 139-48.
23. e Réunion Interdisciplinaire de Chimiothérapie Anti-infectieuse. 1994, 38/C4. Paris.
24. BERGERON MG, SAGINUR R, DESAULNIERS D, et al. Concentrations of teicoplanin in serum and atrial appendages of patients undergoing cardiac surgery. Antimicrob Agents Chemother 1990 ; 34 : 1699-1702.
25. MARTIN C, BOURGET P, ALAYA M, et al. Teicoplanin in cardiac surgery : intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues. Antimicrob Agents Chemother 1997 ; 41 : 1150-55.
26. e Réunion Interdisciplinaire de Chimiothérapie Antiinfectieuse. 1986 ; C272. Paris.
27. WILSON APR, TAYLOR B, TREASURE T, et al. Antibiotic prophylaxis in cardiac surgery: serum and tissue level of teicoplanin, flucloxacillin, and tobramycin. J Antimicrob Chemother 1988 ; 21 : 201-12.
28. LENDERS H, WALLISER D, SCHUMANN K, et al. Teicoplanin-spiegel in tonsillen-, schleimhaut-, knorpel undknochengewebe. Fortschr Antimikrob Antineoplast Chemother 1991 ; 10 : 119-21.
29. NEHRER S, THALLHAMMER F, SCHWAMEIS E, et al. Teicoplanin in the prevention of infection in total HIP replacelment. Arch Orthop Trauma Surg 1998 ; 118 : 32-6.
30. ALBANÈSE J, LEONE M, BRUGEROLLEs B, et al. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemothetr 2000 ; 44 : 1356-8.
31. BRINQUIN L, ROUSSEAU JM, BOULESTEIX G, et al. Vancomycine en perfusion continue dans les méningites à staphylocoques post-neuro-chirurgicales de l'adulte. Presse Med 1993 ; 22 : 1815-7.
32. PFAUSLER B, HARING HP, KAMPFL A, et al. Cerebrospinal fluid (CSF) pharmacokinetics of intravascular vancomycin in patients with staphylococcal ventriculitis associated with external CSF drainage. Clin Infect Dis 1997 ; 25 : 733-5.
33. BERNARD E, PERBOST I, CARLES M, et al. Efficacy and safety of vancomycin constant-rate infusion in the treatment of chronic Gram-positive bone and joint infection. Clin Microbiol Infect 1997 ; 3 : 440-6.
34. DESPLACES N, MAMOUDY P, DUCROQUET F, et al. Vancomycine en perfusion continue et infections ostéo-articulaires à staphylocoques multi-résistants. Med Mal Infect 1997 ; 27 : 969-74.
35. MASSIAS L, DUBOIS C, DELENTDECKER P, et al. Penetration of vancomycin in uninfected sternal bone. Antimicrob Agents Chemother 1992 ; 36 : 2539-41.
36. GRAZIANI A, LAWSON LA, GIBSON GA et al. Vancomycin concentrations in infected and non infected human bone. Antimicrob Agents Chemother 1988 ; 32 : 1320-2.
37. GEORGES H, LEROY O, ALFANDARI S. et al. Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis 1997 ; 16 : 385-8.
38. LAMER C, DEBECO C, SOLER P, et al. Analysis of Vancomycin entry into pulmponary lining fluid by broncho-alveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993 ; 37 : 281-6.
39. CRUCIANI M, GATTI G., LAZZARINI L, et al. Penetration of vancomycin in human lung tissue. J Antimicrob Chemother 1996 ; 38 : 865-9.
40. MARTIN C, ALAYA M, MALLET MN, et al. Penetration of vancomycin into medistinal and cardiac tissue in humans. Antimicrob Agents Chemother 1994 ; 38 : 396-9.
41. TORRES JR, SANDERS CV, LEWIS AC. Vancomycin concentrations in human tissues: preliminary report. J Antimicrob Chemother 1979 ; 5 : 475-7.
42. DRAGO L, DEVECCHI E, FASSINA MC, et al. Serum and bone concentrations of teicoplanin and vancomycin : study in an animal model. Drugs Exp Clin Res 1998 ; 24 : 185-90.
43. HYATT JM, MCKINNON PS, ZIMMER GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antimicrobial agents. Clin Pharm 1995 ; 28 : 143-60.
44. LOWDIN EI, ODENHOLT I, CARS O. In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother 1998 ; 42 : 2739-744.
45. KNUDSEN JD, FURSTED K, ESPERSEN F, et al. Activities of vancomycin and Teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. Antimicrob Agents Chemother 1997 ; 41 : 1910-5.
46. KNUDSEN JD, FURSTED K, RABER S., et al. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob. Agents Chemoter. 2000 ; 44 : 1247-54.
47. CHAMBERS HF, KENNEDY S. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother 1990 ; 34 : 510-4.
48. PEETERMANS WE, HOOGETERP JJ, HAZEKAMP-VANDOKKUM AM. et al. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother 1990 ; 34 : 1869-74.
49. LOPEZ P, GAVALDA J, MARTIN MT et al. Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditis. Antimicrob Agents Chemother 2001 ; 45 : 1387-93.
50. HARDING I, MCGOVAN MP, WHITE LO, et al. Teicoplanin therapy of Staphylococcus aureus septicemia : relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother 2000 ; 45 : 835-41.
51. BANTAR C, DURLACH R, NICOLA F, et al. Efficacy and pharmacodynamics of teicoplanin given daily during the first three days and then on alternate day for methicillin resistant Staphylococcus aureus infections. J Antimicrob Chemother 1999 ; 43 : 737-40.
52. HOULIHAN HH, MERCIER RC, RYBACK MJ. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin resistant Staphylococcus aureus - infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother 1997 ; 41 : 2497-501.
53. JEHL F, KAMILI N, ELKHAILI H et al. Pharmacodynamie in vitro de l'amoxicilline et bactéricidie ex vivo après 1 g per os sur S. pneumoniae résistants à la pénicilline. Méd Mal Infec 1997 ; 27 : 45-57.
54. ELKHAILI H, PETER JD, POMPEI D, et al. Pharmacokinetics in vivo and pharmacodynamic ex vivo/in vitro of meropenem and cefpirome in the Yucatan micropig model : continuous infusion versus intermittent injection. Clinical Microbiology and Infection 1998 ; 4 : 18-26.
55. JEHL F. Pharmacodynamie des antibiotiques : où en sommes-nous ? Antibiotiques 2002 ; 4 : 79-81.
56. SPENCER RC, GOERING R. A critical review of the in-vitro activity of teicoplanin. Int J Antimicrob Agents 1995 ; 5 : 169-77.
57. MAINARDI JL, SHLAES DM, GOERING RV, et al. Decreased Teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J Infect Dis 1995 ; 171 : 1646-50.
58. TENOVER F, LANCASTER MV, HILL BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998 ; 36 : 1020-7.
59. TENOVER F. VRSA, VISA, and GISA : The dilemma behind the name game. Clin Microbiol Newsle. 2000 ; 22 : 49-53.
60. LECLERCQ R, SOUSSY CJ, DRUGEON HB, et al. Influence majeure des lots de milieu de Mueller-Hinton sur les CMI de la teicoplanine vis-à vis des staphylocoques à coagulase négative (SCN) RICAI 2001.
61. WEBER P, LECLERCQ R, MONIOT-VILLE N, et al. Evaluation de l'activité in vitro de la teicoplanine vis-à-vis de Staphylococcus epidermidis par la galerie ATB-Staph Biomérieux, comparée à la technique de référence des CMI en milieu gélosé. RICAI 2002 : 90/P1.
62. JAMES JK, PALMER SM, LEVINE DP et al. Comparision of conventional dosing versus continuous - infusion vancomycin therapy for patients with suspected or documented Gram-positive infections. Antimicrob Agents Chemother 1996 ; 40 : 696-700.
63. LACY MK, TESSIER PR, NICOLA DP, et al. Comparision of vancomycin pharmacodynamics (1 g every 12 hours or 24 hours) against methicillin-resistant staphylococci. Int J Antimicrob Agents 2000 ; 15 : 25-30.
64. WANG JT, FANG CT, CHEN YC et al. Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother 2001 ; 47 : 24.
65. LEADER WG, CHANDLER MH, CASTIGLIA M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 1995 ; 28 : 327-42.
66. GRANINGER W, WENISH C, WIESINGER E et al. Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 1995 ; 14 : 643-7.
67. GRANINGER W, PRESTERL E, WENISH C, et al. Management of serious staphylococcal infections in the outpatient setting. Drugs 1997 ; 54 : 21-8.
68. MARRA F, CAIRNS B, JEWESSON P. Vancomycin serum concentration monitoring. The middle ground is best. Clin Pharmacokinet 1996 ; 12 : 105-18.
69. MACGOVAN. Pharmacodynamics, pharmacokinetics, and therapeutics drug monitoring of glycopeptides. Ther Drug Monitor 1998 ; 20 : 473-7.
70. WILSON AR, GRUNEBERG RN, NEU H. A critical review of the dosage of teicoplanin in Europe and in the USA. Int J Antimicrob Agents 1994 ; 4 : 1-30.
71. JEHL F. Tolerance and residual serum concentrations of teicoplanin administered intra-venously to healthy volunteers at 15 mg/kg on alternate days as compared to 6 mg/kg every day (Study M000507/1 L 03) Rapport d'expertise pharmacocinétique. Laboratoires Avantis, data on file.